JPMorgan Conference: Indian Generics’ US Edge- 45-50% Share Shields From Tariff Overhang|Bansi Desai #ETNOW
JPMorgan Conference: Indian Generics’ US Edge- 45-50% Share Shields From Tariff Overhang|Bansi Desai
JPMorgan’s Bansi Desai highlights Indian generics’ pivotal US role (45-50% market share), currently exempt from Trump tariffs pending Section 232 probe. Larger firms like Lupin, Cipla, Sun resilient via US plants; 10-20% tariffs absorbable. CDMO insulated, capturing 4% of $255B global market by 2025 via outsourcing, cost edges, and complex tech like ADCs.
#trumptariffs #indianpharma #genericsus #cdmogrowth #section232 #lupincipla #pharmaoverhang #indiaexports #navratrimarkets #atmanirbharpharma #etnow
control your money with economic times now.
YouTube Channel – https://www.youtube.com/@ETNow
Subscribe To ET Now For Latest Updates On Stocks Market News , Business News, Company News, IPO & More | https://bit.ly/SubscribeToETNow
Subscribe Now To Our Network Channels :-
ET Now Swadesh: https://www.youtube.com/etnowswadesh
Times Now: http://goo.gl/U9ibPb
Social Media Links :-
Twitter – http://goo.gl/hA0vDt
Facebook – http://goo.gl/5Lr4mC
Website – https://ift.tt/2dIpjeB
Follow us on Google News for latest updates
ET Now: https://ift.tt/xBluDnG
Times Now Navbharat: https://bit.ly/3zDaKJo
Times Now : https://bit.ly/3CyrrYg
Zoom: https://bit.ly/3CEK0dv
Thank you for your support in keeping this website running.💛
View on “Tokyo Trend News”
コメントを送信